Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL362022 | 0.88 | BACE1 (1.00) | BACE1 | |
| SCHEMBL362674 | 0.88 | BACE1 (1.00) | BACE1 | |
| SCHEMBL362957 | 0.86 | BACE1 (1.00) | BACE1 | |
| SCHEMBL360570 | 0.86 | BACE1 (1.00) | BACE1 | |
| SCHEMBL360715 | 0.86 | BACE1 (1.00) | BACE1 | |
| SCHEMBL361370 | 0.86 | BACE1 (1.00) | BACE1 | |
| SCHEMBL16857645 | 0.86 | BACE1 (0.68) | BACE1 | |
| SCHEMBL16857619 | 0.86 | BACE1 (0.68) | BACE1 | |
| SCHEMBL15678387 | 0.86 | BACE1 (0.90) | BACE1 | |
| SCHEMBL15345230 | 0.85 | BACE1 (0.84) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2014-05-08 | — | — | US | disclosed |
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2014-05-08 | — | — | US | disclosed |
| US-20130281449-A1 | Oxazine Derivatives and their Use in the Treatment of Neurological Disorders | NOVARTIS AG (CH) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281449-A1 | Oxazine Derivatives and their Use in the Treatment of Neurological Disorders | GRIK5, OTC, GRIN2C | BACE1 74/4885 |
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | BACE2, BACE1, IAPP | BACE1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.